Clinical Outcomes and Effectiveness of CRLX101 for Solid Tumors: A Systematic Review and Meta-analysis

CONCLUSION: Our meta-analysis shows that CRLX101 outperforms camptothecin in PFS despite its inferior OS. Unresolved pharmacology limits carrier-mediated drug therapeutic application. Carrier-mediated dosages may differ from normal formulations because they are rarely studied.PMID:38415437 | DOI:10.2174/0109298673263933231206101556

Source: Current Medicinal Chemistry - February 28, 2024 Category: Chemistry Authors: Nahal Shamaeizadeh Erfan Sadeghi Jaleh Varshosaz Source Type: research